WuXi Biologics and Vertex reach licensing and research service agreement for innovative trispecific T-cell engager

Gelonghui, February 3rd｜WuXi Biologics announced that it has signed a licensing and research services agreement with Vertex Pharmaceuticals (NASDAQ: VRTX) for an innovative trispecific T-cell engager (TCE). Vertex plans to use it for the treatment of B cell-mediated autoimmune diseases. Under the terms of the agreement, Vertex will obtain global exclusive rights for the development and commercialization of this preclinical-stage trispecific TCE intended for the treatment of B cell-mediated autoimmune diseases. WuXi Biologics will receive an upfront payment and is eligible to receive milestone payments related to development, registration, and sales, as well as royalties on product sales after launch. In addition, WuXi Biologics will provide integrated contract research and development services for its innovative TCE.